primary cutaneous anaplastic large cell lymphoma (pcALCL)

November 13, 2017November 13, 2017

FDA Approves Adcetris for Most Common Subtypes of Cutaneous T-cell Lymphoma

News

The U.S. Food and Drug Administration (FDA) has approved Seattle Genetics’ Adcetris (brentuximab vedotin) for the treatment of adults with the two most common subtypes of cutaneous T-cell lymphoma (CTCL) — ... Read more

June 21, 2017

Seattle Genetics Asks FDA to Approve Adcetris for Expanded Set of Lymphoma Patients

News

Seattle Genetics is asking the U.S. Food and Drug Administration to approve Adcetris (brentuximab vedotin) for an expanded set of cutaneous T-cell lymphoma patients. The agency has yet to authorize Adcetris for CTCL. A supplemental Biologics ... Read more

November 15, 2016

FDA Grants Breakthrough Therapy Designation to Adcetris for Certain Lymphoma Subtypes

News

The U.S. Food and Administration (FDA) has granted Breakthrough Therapy Designation to Seattle Genetics’ Adcetris (brentuximab vedotin) as a therapy for the most common subtypes of cutaneous T-cell lymphoma (CTCL), ... Read more